Brazil clears two more synthetic semaglutide pens as interchangeable
Brazil's regulator has cleared more low-cost semaglutide pens as substitutes for the branded product, creating the first real-world look at how generic competition moves prices in a major market.
Brazil's health regulator, ANVISA, has approved two more synthetic semaglutide pens — a generic from EMS and Germed's Semaclique — as interchangeable substitutes for Ozivy, the first synthetic semaglutide pen the agency cleared in May 2026 [1]. With those clearances, Brazil now has at least seven post-patent semaglutide registrations within about five months of the drug's Brazilian patent expiry in March 2026 [1].
Semaglutide is the molecule sold by Novo Nordisk as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight management. "Interchangeable" status matters because it is the regulatory label that allows a pharmacy to swap one product for another at the counter, rather than requiring a new prescription for each brand.
What the sources confirm
The available sources document the outline of Brazil's post-patent race, but not every company detail. ANVISA approved Ozivy as the first synthetic semaglutide pen in May 2026, a decision described as establishing a regulated pathway for domestic competition and adding price pressure on branded injectable semaglutide [1]. Reuters separately reported that Sandoz received approval for its generic semaglutide in Brazil in July, and is eyeing a Canadian launch this year for patients with diabetes [2]. The sources provided here do not name Sun Pharmaceutical or Hypera Pharma in connection with a July Brazilian approval, so that specific pairing is not confirmed by this reporting.
Brazil is the biggest prize in the region. It accounted for 59.82% of South American GLP-1 revenue in 2025, in a regional market estimated at USD 1.62 billion in 2025 and projected to reach USD 2.58 billion by 2031, an 8.34% compound annual growth rate [1]. Semaglutide alone held 51.35% of South American GLP-1 revenue in 2025, and injectable pens made up 87.42% of the market by route of administration [1]. Novo Nordisk, for its part, announced an 8 billion DKK (about USD 1.26 billion) production investment in Montes Claros, Brazil, intended to expand local capacity [1].
How far prices fall is still unknown. Sandoz's chief financial officer declined to put a value on the potential upside from generic GLP-1 medicines, saying forecasts remain highly uncertain, but said the opportunity would be measured in "billions" of dollars and that the market could expand to between two and seven times its current size once lower-cost copies become available [2]. Sandoz's own 2025-to-2035 sales targets exclude any contribution from generic GLP-1 drugs [2].
Why it matters for patients
For US readers, nothing changes at the pharmacy counter today. Brazil's patent situation is not the United States', and none of these pens are approved for US sale. What Brazil offers is data: it is the largest market where branded semaglutide and multiple approved copies are now competing head to head, and pricing there will be watched as a preview of what happens elsewhere when exclusivity ends.
The Brazilian experience also shows the limits of approvals alone. Out-of-pocket cost remains a major obstacle across South America, where branded tirzepatide and high-dose semaglutide can exceed the budgets of many middle-income households, leading patients to delay or stop treatment [1]. Reimbursement lags matter too: a 2026 FIFARMA WAIT Indicator reported availability delays of 22 to 43 months after approval for innovative cardiometabolic medicines across 10 South American countries, with delays pronounced in Chile, Brazil and Panama [1]. Chile excludes GLP-1 medicines from its public system entirely [1].
Quality oversight is the other open question. The market report notes that regulatory review remains important for synthetic and biosimilar products and that competition does not remove the need for quality controls [1]. ANVISA has previously cited manufacturing noncompliance and illegal sales without prescriptions in the region [1].
What happens next
Key dated markers so far: the Brazilian semaglutide patent expired in March 2026 [1]; ANVISA approved a multidose Mounjaro (tirzepatide) pen in March 2026 covering six concentration formats in one device [1]; Ozivy was cleared in May 2026 [1]; and a further generic approval followed in July [2]. Actual Brazilian price changes after these launches have not yet been reported in these sources, and no US approval timeline for generic semaglutide is addressed.
Sources
Semaglutides.org is for information only and is not medical advice. Always talk to a licensed healthcare provider about your own care. Some links to telehealth services are affiliate links, labeled where they appear.